TRIM63 and hereditary clear cell renal cell carcinoma: Given its regulation by TFE3 and TFEB [16], TRIM63 RNA in situ hybridization (RNA-ISH) is currently clinically performed in our department, with primary use by genitourinary pathologists to detect MiTF-family aberration associated (formerly referred to as “translocation-associated”) renal cell carcinomas.